SynthesisBMC cancer2025
The relationship between toll-like receptors 9 gene rs5743836 polymorphism and lymphoma risk: a meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe performed this meta-analysis to investigate the potential relationship between the polymorphism of the rs5743836 gene of toll-like receptors 9 (TLR9) and the risk of lymphoma.
methodsStatistical analysis of all data was performed using Stata 15.0. Heterogeneity tests for all selected studies were performed using the Chi-square-based Q test (P < 0.05 suggesting heterogeneity) and the I-square test, and the pooled odds ratios (ORs) were calculated. Sensitivity analysis was also performed to evaluate the stability of the pooled results by funnel plot. Begg's regression test was also performed for possible publication bias in three genetic models.
resultsWe found that the TLR9 gene rs5743836 was significantly associated with the risk of lymphoma in the dominant genetic model (OR = 1.54, 95%CI = 1.03-2.32, P = 0.036). However, we found that the TLR9 gene rs5743836 was not significantly associated with lymphoma risk in the recessive genetic model (OR = 1.04, 95%CI = 0.65-1.65, P = 0.873) and the allele genetic model (OR = 1.28, 95%CI = 0.93-1.76, P = 0.130). We also performed a sensitivity analysis by removing each eligible study, we found that there was no significant change in the merging effect and pooled ORs, which indicates good stability of the results of this study. Publication bias was tested using Begg's funnel plot, and the results suggested that no publication bias was observed in dominant genetic models (TC + CC vs. TT, P = 0.3486), recessive genetic models (CC vs. TC + TT, P = 0.829), and allelic genetic model (C vs. T, P = 0.463).
conclusionsIn conclusion, the results of this meta-analysis indicated that the TLR9 gene rs5743836 was significantly associated with lymphoma risk in the dominant genetic model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.